Molecular genetics of colorectal cancer: An overview

Current Colorectal Cancer Reports

Volumn 2, Issue 2, 2006, Pages 53-59

  Hisamuddin, Irfan M ^a   Yang, Vincent W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247894942     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-006-0002-2     Document Type: Review

References (65)

1. American Cancer Society: Cancer Facts & Figures 2005 http://www.cancer.org/downloads/STT CAFF2005f4PWSecured.pdf. Accessed January 31, 2006.
2. Hisamuddin IM, Yang VW: Genetics of colorectal cancer. MedGenMed 2004, 6:13-19.
3. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
4. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
5. Sparks AB, Morin PJ, Vogelstein B, et al.: Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998, 58:1130-1134.
6. de la Chapelle A: Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004, 4:769-780.
7. Kinzler KW, Vogelstein B: Landscaping the cancer terrain. Science 1998, 280:1036-1037.
8. Cruz-Correa M, Giardiello FM: Familial adenomatous polyposis. Gastrointest Endosc 2003, 58:885-894.
9. Kinzler KW, Nilbert MC, Su LK, et al.: Identification of FAP locus genes from chromosome 5q21. Science 1991, 253:661-665.
10. Nishisho I, Nakamura Y, Miyoshi Y, et al.: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991, 253:665-669.
11. Groden J, Thliveris A, Samowitz W, et al.: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66:589-600.
12. Soravia C, Berk T, Madlensky L, et al.: Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998, 62:1290-1301.
13. Laken SJ, Petersen GM, Gruber SB, et al.: Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997, 17:79-83.
14. Gruber SB, Petersen GM, Kinzler KW, et al.: Cancer, crash sites, and the new genetics of neoplasia. Gastroenterology 1999, 116:210-212.
15. Sieber OM, Lipton L, Crabtree M, et al.: Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003, 348:791-799.
16. Halford SE, Rowan AJ, Lipton L, et al.: Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol 2003, 162:1545-1548.
17. Mecklin J P, Jarvinen HJ: Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). Cancer 1991, 68:1109-1112.
18. Papadopoulos N, Lindblom A: Molecular basis of HNPCC: mutations of MMR genes. Hum Mutat 1997, 10:89-99.
19. Markowitz S, Wang J, Myeroff L, et al.: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
20. Souza RF, Appel R, Yin J, et al.: Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 1996, 14:255-257.
21. Rampino N, Yamamoto H, Ionov Y, et al.: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969.
22. Hemminki A, Markie D, Tomlinson I, et al.: A serine/thre-onine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391:184-187.
23. Jenne DE, Reimann H, Nezu J, et al.: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998, 18:38-43.
24. Sayed MG, Ahmed AF, Ringold JR, et al.: Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol 2002, 9:901-906.
25. Olschwang S, Serova-Sinilnikova OM, Lenoir GM, et al.: PTEN germ-line mutations in juvenile polyposis coli. Nat Genet 1998, 18:12-14.
26. Marsh DJ, Kum JB, Lunetta KL, et al.: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999, 8:1461-1472.
27. Yang VW: APC as a checkpoint gene: the beginning or the end? Gastroenterology 2002, 123:935-939.
28. Midgley CA, White S, Howitt R, et al.: APC expression in normal human tissues. J Pathol 1997, 181:426-433.
29. Nathke IS: The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu Rev Cell Dev Biol 2004, 20:337-366.
30. van Es JH, Giles RH, Clevers HC: The many faces of the tumor suppressor gene APC. Exp Cell Res 2001, 264:126-134.
31. Reya T, Clevers H: Wnt signaling in stem cells and cancer. Nature 2005, 434:843-850.
32. Gregorieff A, Clevers H: Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005, 19:877-890.
33. Bhanot P, Brink M, Samos CH, et al.: A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996, 382:225-230.
34. Tamai K, Semenov M, Kato Y, et al.: LDL-receptor-related proteins in Wnt signal transduction. Nature 2000, 407:530-535.
35. Pinson KI, Brennan J, Monkley S, et al.: An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000, 407:535-538.
36. Behrens J, von Kries JP, Kuhl M, et al.: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382:638-642.
37. He TC, Sparks AB, Rago C, et al.: Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
38. Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
39. Miyoshi Y, Nagase H, Ando H, et al.: Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992, 1:229-233.
40. Jin LH, Shao QJ, Luo W, et al.: Detection of point mutations of the Axin1 gene in colorectal cancers. Int J Cancer 2003, 107:696-699.
41. Webster MT, Rozycka M, Sara E, et al.: Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 2000, 28:443-453.
42. Smith KJ, Levy DB, Maupin P, et al.: Wild-type but not mutant APC associates with the microtubule cytoskeleton. Cancer Res 1994, 54:3672-3675.
43. Su LK, Burrell M, Hill DE, et al.: APC binds to the novel protein EB1. Cancer Res 1995, 55:2972-2977.
44. Matsumine A, Ogai A, Senda T, et al.: Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science 1996, 272:1020-1023.
45. Fodde R, Kuipers J, Rosenberg C, et al.: Mutations in the APC tumor suppressor gene cause chromosomal instability. Nat Cell Biol 2001, 3:433-438.
46. Kaplan KB, Burds AA, Swedlow JR, et al.: A role for the adenomatous polyposis coli protein in chromosome segregation. Nat Cell Biol 2001, 3:429-432.
47. Leslie A, Stewart A, Baty DU, et al.: Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility. Genes Chromosomes Cancer 2005, 45:126-135.
48. Hollstein M, Sidransky D, Vogelstein B, et al.: p53 mutations in human cancers. Science 1991, 253:49-53.
49. Baker SJ, Fearon ER, Nigro JM, et al.: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244:217-221.
50. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310.
51. Momand J, Zambetti GP, Olson DC, et al.: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
52. Honda R, Yasuda H: Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. Embo J 1999, 18:22-27.
53. Wsierska-Gadek J, Horky M: How the nucleolar sequestration of p53 protein or its interplayers contributes to its (re)-acti-vation. Ann N Y Acad Sci 2003, 1010:266-272.
54. Agarwal ML, Taylor WR, Chernov MV, et al.: The p53 network. J Biol Chem 1998, 273:1-4.
55. Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
56. el-Deiry WS, Tokino T, Velculescu VE, L et al.: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
57. Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
58. Hermeking H, Lengauer C, Polyak K, et al.: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997, 1:3-11.
59. Malumbres M, Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
60. Shields JM, Pruitt K, McFall A, et al.: Understanding Ras: "it ain't over 'til it's over.'" Trends Cell Biol 2000, 10:147-154.
61. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
62. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br J Cancer 2001, 85:692-696.
63. Rajagopalan H, Bardelli A, Lengauer C, et al.: Tumorigen-esis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
64. Tuveson DA, Shaw AT, Willis NA, et al.: Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004, 5:375-387.
65. Janssen KP, el-Marjou F, Pinto D, et al.: Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology 2002, 123:492-504.